Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma (RTKI)

Rennes University Hospital

Status: Completed

Conditions: Metastatic Clear Cell Renal Cell Carcinoma

Treatments: Drug: Sunitinib

Study type: Observational

Funder types: Other

Identifiers

NCT02848768

35RC14_9896

Details and patient eligibility

About

The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma

Enrollment: 45 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with metastatic ccRCC
• Underwent nephrectomy at the University Hospital of Rennes
• treated by sunitinib first line treatment

Exclusion criteria

• translocation renal cell carcinoma
• other targeted therapies before the sunitinib